Third-line secukinumab tied to reduced survival in axSpA, axPsA
22 Aug 2025
byStephen Padilla
A real-word study in Argentina has found poor access to secukinumab treatment among patients with public health insurance than those using the social security system or private health coverage. Furthermore, use of secukinumab as third-line therapy or higher is associated with less survival.
Third-line secukinumab tied to reduced survival in axSpA, axPsA
22 Aug 2025
